NewAmsterdam Pharma

10/28/2025

Even when taking statins, many ASCVD patients continue to face significant residual cardiovascular risk. Professor Stephen Nicholls highlights that while lowering LDL-C remains crucial, it’s not the only factor driving heart disease.

10/20/2025

We are excited to announce that our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. These data were first presented at . 🔓 Read the open access article: https://bit.ly/47bwIGd

09/30/2025

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

09/29/2025

Together, we won’t miss a beat.

This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death.

This year’s theme, “Don’t Miss a Beat,” is a powerful reminder to stay proactive about heart health. We’re advancing research in pursuit of a future where heart disease is no longer the #1 killer worldwide.

https://bit.ly/4nugjUo

09/24/2025

09/24/2025

Over 7 million Americans are living with Alzheimer’s disease. By 2050, that number is projected to reach nearly 13 million.

Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: https://bit.ly/4nQEvQI

09/22/2025

Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission.

Learn more about us: https://www.newamsterdampharma.com/aboutus?utm_source=fb&utm_medium=organic&utm_campaign=culture&utm_content=bj

09/08/2025

Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: https://bit.ly/46co8GK

09/01/2025

Professor Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN and BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in the Journal of the American College of Cardiology: https://bit.ly/4n7MSGZ

08/19/2025

Lowering LDL-C is about reducing the risk of heart attacks, strokes, and the need for costly interventions – not just hitting a target.

Dr. Maya Safarova explains why goal attainment should be the standard, not the exception.

👇 Learn about the limitations of current lipid-lowering therapies.
https://bit.ly/41GZ1KI

08/14/2025

Did you know cholesterol plays a critical role in brain health? While it’s essential, too much or poorly regulated cholesterol can contribute to the buildup of amyloid plaque and tau tangles, key markers of Alzheimer’s disease.

Explore how cholesterol works in the brain: https://bit.ly/45OQTu2

08/07/2025

A growing body of research indicates CETP plays a central role in both systemic and brain lipid metabolism. Genetic studies show those with naturally low CETP levels are at a lower risk of Alzheimer’s disease, particularly in ApoE4 carriers. Learn more about this emerging link: https://www.newamsterdampharma.com/lipid-related-conditions/?utm_source=fb&utm_medium=organic&utm_campaign=other-conditions